Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Taiyen Biotech Co., Ltd. (1737.TW)
Táinán, TW
Established in 1952 and headquartered in Tainan, Taiwan, Taiyen Biotech Co., Ltd. is a multifaceted enterprise engaged in the global production and distribution of salt-based goods. The company offers a wide-ranging portfolio that includes various salt and seawater-derived chemical products, alongside an array of personal care items such as bath salts, specialty soaps, and shampoos. Beyond hygiene products, their offerings extend to beverages, drinking water, and oral and optical care solutions like toothpaste, mouthwash, and contact lens maintenance fluids. Taiyen also provides specialized salts for cleaning produce, as well as food items and additives. Furthermore, the company manufactures pharmaceutical products, encompassing both cosmetic formulations and environmental health medications. Its operations also include the import and export of general consumer goods and beauty products, complemented by expert consulting services in industrial salt technology, covering supply, implementation, and management.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.32% | -0.32% | -1.72% | -0.94% | -1.10% | -0.79% | -3.97% | -6.12% | -1.56% | +17.13% | +22.28% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Household & Personal Products: +3.3%+2.2% Q1'26: -3.6% (vs Q1'25)
-
EPS growth Household & Personal Products: +8.8%+8.1% Q1'26: -4.1% (vs Q1'25)
-
FCF margin FCF growth · Household & Personal Products: +44.8%+5.8% Q1'26: +11.7% (vs Q1'25)
-
EBIT margin Household & Personal Products: +9.9%+14.4% ★ Q1'26: +15.4% (vs Q1'25)
-
ROIC Household & Personal Products: +8.2%+7.2% Q1'26: +7.3% (vs Q1'25)
-
Share dilution Household & Personal Products: +0.2%-1.9% ★ Q1'26: +1.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Household & Personal Products: -0.51×0.31× ★ Q1'26: 0.46× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-05 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-04 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 2/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 2/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 2/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 2/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 2/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 2/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 2/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 2/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 2/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 2/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 2/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR Portfolio Emerging Markets ETF SPEM | 0.02% | 3.22M | 0.07% |
| 2 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 390.0K | 0.06% |
| 3 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 40.1K | 0.46% |
| 4 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 151.4K | 0.39% |
| 5 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.00% | 8.9K | 0.65% |
| 6 | Vanguard ESG International Stock ETF VSGX | 0.00% | 79.3K | 0.10% |
| 7 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 14.4K | 0.48% |
| 8 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 32.5K | 0.26% |
| 9 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.61M | 0.06% |
| 10 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 84.9K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| An-Ping | Director of Administrative Department & Representative Director | — | — |
| Chieh-Han Lee | Vice President & Director of Corporate Development Department | — | male |
| Mei-Wen Chen | Director of Branding & Marketing Department | — | female |
| Mei-Yu Chuang | Chief Internal Auditor | — | — |
| Tung-Hsuan Yang | Director of Legal Affairs Office | — | male |
| Wei Su | Director of Financial Accounting Department | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1737.TW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
